Radioligand therapy significantly prolongs progression-free survival in metastatic GEP-NETs

Results of the Phase III COMPETE objective proceedings amusement that the targeted radiotherapeutic cause [177Lu]Lu-edotreotide importantly prolonged progression-free endurance successful patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared with targeted therapy with everolimus.